|
GeneraMedix Inc. announces FDA approval and launch of three generic injectable products |
|
|
|
09 Aug 2007 |
GeneraMedix Inc. has received FDA approval; and has launched Carboplatin Injection, Fluorouracil Injection, USP, and Methotrexate Injection, USP
LIBERTY CORNER, NJ, USA | August 7, 2007 | GeneraMedix Inc. has received FDA approval; and has launched Carboplatin Injection, Fluorouracil Injection, USP, and Methotrexate Injection, USP.
GeneraMedix offers the following presentations: Carboplatin Injection: 10 mg/mL; 5 mL, 15 mL and 45 mL vials, Fluorouracil Injection, USP: 50 mg/mL; 10 mL, 20 mL, 50 mL and 100 mL vials and Methotrexate Injection, USP: 25 mg/mL; 2 mL, 10 mL and 40 mL vials, preservative free.
These are the first products launched resulting from a long term, multi- product partnership between GeneraMedix Inc. and Intas Pharmaceuticals Ltd., a leading India based pharmaceutical company. Under the terms of the partnership, Intas developed the products and provides the commercial supplies.
Ronald F. Quadrel, President and CEO of GeneraMedix, Inc. stated, "We are very pleased to enter into this strategic relationship with Intas Pharmaceuticals as we continue to build our generic injectable product portfolio. The Intas agreement reinforces our long term commitment to provide a broad range of generic injectable products to U.S. hospitals, surgery centers and clinics."
Samir Mehta, Executive Vice President (USA) of Intas Pharmaceuticals Ltd said, "We are very pleased with this strategic alliance, integrating our product development and manufacturing capabilities with the regulatory affairs, marketing and distribution capabilities of GeneraMedix. The launch of these three products is the first step towards the realization of this strategy."
About Intas Pharmaceuticals Ltd.
Intas Pharmaceuticals was founded in 1976, and has grown to become one of India's top twenty (20) pharmaceutical companies. Intas specializes in product development and manufacturing and has a presence in more than forty-two (42) countries around the world. Intas has a state-of-the-art cytotoxic manufacturing facility. The company received FDA approval at its Matoda, India facility in 2006. Additional information is available at the company's website at http://www.intaspharma.com.
About GeneraMedix Inc.
GeneraMedix Inc. is a privately held pharmaceutical company offering high quality generic injectable products to U.S. hospital and specialty markets. In addition to its products already marketed, GeneraMedix has a significant number of injectable products under development, as well as a number of products under FDA review. Headquartered in Liberty Corner, New Jersey, the company was founded in July, 2004. Additional information is available on the company's website at http://www.generamedix.com.
SOURCE: GENERAMEDIX, INC.
|
